Oral Drug Shows Benefit for Notalgia Paresthetica in Mid-Stage Trial
A selective kappa opioid receptor agonist in patients with notalgia paresthetica led to “modestly” greater improvements in itchiness over placebo, but was associated with adverse events, a randomized phase II trial showed. At 8 weeks, improvements in average itchiness was significantly greater with oral difelikefalin (Korsuva) versus placebo on the Worst Itch Numeric Rating Scale […]